Draft Resolutions of
the Ordinary General Meeting of Shareholders

The General Meeting of Shareholders of Antibiotice S.A., a trading company established and operating according to the Romanian law, registered at the Trade Register Office Iasi attached to the Court of Iasi, under the no. **J1991000285223**, unique registration code RO1973096, headquartered in 1 Valea Lupului St., Iasi, Romania, having subscribed and paid-up capital in the amount of 67,133,804 LEI divided in 671,338,040 ordinary registered shares, with a nominal value of 0.10 lei each,

convened by the announcement published in the Official Gazette of Romania, Part IV, no. 5815/19.08.2026 and in Evenimentul no. 10767 dated on 19.08.2026, (and republished in the Official Gazette of Romania, Part IV, no. .../… and in Evenimentul no. ……… dated on …………)

according to the provisions of Law no. 31/1990 on trading companies, republished, with the subsequent amendments and completions, Law no. 24/2017 on issuers of financial instruments and market operations, republished, FSA Regulation no. 5/2018 on issuers of financial instruments and market operations, with the subsequent amendments and completions, Government Emergency Ordinance no. 109/2011 on corporate governance of public enterprises and provisions of the company’s Articles of Association,

convened on **30.09.2026**, at 10 a.m., for the first call/second call in an Ordinary Session at Antibiotice headquarters, gathering shareholders representing ………% of the share capital, respectively …………% of the total no. of voting rights, statutory and legally constituted,

following the debates,

DECIDES:

Resolution no.1: With the " in favour "/"against" votes of the shareholders representing ...% of the total votes cast, the General Meeting of Shareholders approves/does not approve the Financial Report for the first half of 2026, consisting of:

a. simplified half-yearly financial statements;
b. half-yearly report of the board of directors;
c. the declaration of the responsible persons;
d. the full report of the audit firm.

Resolution no.2: With the " in favour "/"against" votes of the shareholders representing ...% of the total votes cast, the General Meeting of Shareholders approves/does not approve the allocation of 50% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.019877174 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

Resolution no.3: With the " in favour "/"against" votes of the shareholders representing ...% of the total votes cast, the General Meeting of Shareholders approves/does not approve the allocation of 90% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.035778913 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

Resolution no.4: With the " in favour "/"against" votes of the shareholders representing ...% of the total votes cast, the General Meeting of Shareholders approves/does not approve the ratification of the Management Board's Decision no. 1 of 25.06.2026, regarding:

- the approval of the increase in the multicurrency, multiproduct, cash and non-cash credit facility, contracted with UniCredit Bank SA from the amount of RON 91,500,000 to the amount of RON 141,000,000.
- the approval/maintenance of the guarantee of the facility mentioned above, in the amount of RON 141,000,000, which will be contracted with UniCredit Bank SA with the following:
  - Mortgage on the current and future accounts opened by Antibiotice SA at UniCredit Bank SA.
- approval of the authorization of Mr. Ioan Nani as General Director to sign on behalf of Antibiotice SA all documents/credit contracts and their accessories, necessary and related to the contracting and implementation of the credit facility in the total amount of RON 141,000,000 from UniCredit Bank SA, as well as all the subsequent additional documents related to the documents/credit contracts and accessories related to this credit.

Resolution no.5: With the " in favour "/"against" votes of the shareholders representing ...% of the total votes cast, the General Meeting of Shareholders approves/does not approve the rectification of the Decision no. 3 of the Ordinary General Meeting of Shareholders dated 06.11.2025, in order to remedy a material error, as follows:
Resolution No. 3 of the Ordinary General Meeting of Shareholders dated November 6, 2025—stating "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of a director position at Antibiotice S.A. is acknowledged"—is rectified to read: "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of the director position held by Mr. Cătălin-Codruț Popescu is acknowledged, effective as of November 6, 2025."

These decisions shall be signed today **30.09.2026** at the company's headquarters, in two original copies.

President of the Management Board,
Ionut-Sebastian IAVOR